BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Doherty B, Nambudiri VE, Palmer WC. Update on the Diagnosis and Treatment of Cholangiocarcinoma. Curr Gastroenterol Rep. 2017;19:2. [PMID: 28110453 DOI: 10.1007/s11894-017-0542-4] [Cited by in Crossref: 100] [Cited by in F6Publishing: 98] [Article Influence: 16.7] [Reference Citation Analysis]
Number Citing Articles
1 Kim SW, Choi JW, Kim JM, Yoon HY, Bae K, Yoon KA, Kim JH. Case report: Toceranib as adjuvant chemotherapy in a dog with incompletely resected combined hepatocellular-cholangiocarcinoma. Front Vet Sci 2022;9:963390. [PMID: 36686162 DOI: 10.3389/fvets.2022.963390] [Reference Citation Analysis]
2 Cremen S, Kelly ME, Gallagher TK. The role of neo-adjuvant therapy in cholangiocarcinoma: A systematic review. Front Oncol 2022;12:975136. [PMID: 36568243 DOI: 10.3389/fonc.2022.975136] [Reference Citation Analysis]
3 Zhang Z, Wang X, Nie P, Qin Y, Shi J, Xu S. DEPDC1B promotes development of cholangiocarcinoma through enhancing the stability of CDK1 and regulating malignant phenotypes. Front Oncol 2022;12:842205. [PMID: 36568241 DOI: 10.3389/fonc.2022.842205] [Reference Citation Analysis]
4 Lee M, Jung HS, Cho YJ, Yun WG, Han Y, Kim H, Kwon W, Jang JY. Oncological outcome of proximal and middle extrahepatic bile duct cancer according to surgical extent (Is hilar resection oncologically acceptable in proximal and middle extrahepatic bile duct cancer?). HPB (Oxford) 2022;24:2167-74. [PMID: 36253267 DOI: 10.1016/j.hpb.2022.09.009] [Reference Citation Analysis]
5 Zhang D, Qi F, Sun W, Zhao G, Wang D, Zhou S, Liu Z, Lu Z. Influencing factors of biliary fistula after radical resection of hilar cholangiocarcinoma: a prospect cohort. Eur J Med Res 2022;27:214. [DOI: 10.1186/s40001-022-00851-4] [Reference Citation Analysis]
6 Gadaleta-Caldarola G, Rizzo A, Dadduzio V, Lombardi L, Gadaleta-Caldarola A, Infusino S, Cusmai A, Citrigno C, Palmiotti G. Pemigatinib in Intrahepatic Cholangiocarcinoma: A Work in Progress. Curr Oncol 2022;29:7925-31. [PMID: 36290903 DOI: 10.3390/curroncol29100626] [Reference Citation Analysis]
7 Li H, Ding H, Wang Y, Zhang F, Song Y, Qiu X, Pons J. Validated UPLC-MS/MS Method for Determination of Futibatinib and Its Pharmacokinetics in Beagle Dogs. Journal of Chemistry 2022;2022:1-7. [DOI: 10.1155/2022/8316403] [Reference Citation Analysis]
8 Dall'magro AK, Dogenski LC, Bade P, Cé LC, Dall'magro E, De Carli JP. Mandibular metastasis of primary extrahepatic biliary carcinoma: Case report. International Journal of Surgery Case Reports 2022;98:107498. [DOI: 10.1016/j.ijscr.2022.107498] [Reference Citation Analysis]
9 Chiawpanit C, Panwong S, Sawasdee N, Yenchitsomanus P, Panya A. Genistein Sensitizes Human Cholangiocarcinoma Cell Lines to Be Susceptible to Natural Killer Cells. Biology 2022;11:1098. [DOI: 10.3390/biology11081098] [Reference Citation Analysis]
10 Chen R, Zhang Y, Lin K, Huang D, You M, Lai Y, Wang J, Hu Y, Li N. Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers. Front Pharmacol 2022;13:871262. [DOI: 10.3389/fphar.2022.871262] [Reference Citation Analysis]
11 Zhou B, Yang F, Qin L, Kuai J, Yang L, Zhang L, Sun P, Li G, Wang X. Computational study on novel natural compound inhibitor targeting IDH1_R132H. Aging (Albany NY) 2022;14. [PMID: 35802554 DOI: 10.18632/aging.204162] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Xie C, Huang Z, Huang Z, Zhang X, Lou S. microRNA-206 Suppresses Cholangiocarcinoma Cell Growth and Invasion by Targeting Jumonji AT-Rich Interactive Domain 2. Dig Dis Sci 2022;67:2994-3005. [PMID: 34240323 DOI: 10.1007/s10620-021-07121-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Shi Z, Zhou L, Zhou Y, Jia X, Yu X, An X, Han Y. Inhibition of ClC-5 suppresses proliferation and induces apoptosis in cholangiocarcinoma cells through the Wnt/β-catenin signaling pathway. BMB Rep 2022;55:299-304. [DOI: 10.5483/bmbrep.2022.55.6.044] [Reference Citation Analysis]
14 Wang X, Zhou X, Zhang L, Zhang X, Yang C, Piao Y, Zhao J, Jin L, Jin G, An R, Ren X. Crowberry inhibits cell proliferation and migration through a molecular mechanism that includes inhibition of DEK and Akt signaling in cholangiocarcinoma. Chin Med 2022;17:69. [PMID: 35698073 DOI: 10.1186/s13020-022-00623-6] [Reference Citation Analysis]
15 Chen T, Wang H, Yan H. miR-28-5p inhibits cholangiocarcinoma progression and predicts good prognosis of patients. Cell Cycle 2022;:1-12. [PMID: 35670491 DOI: 10.1080/15384101.2022.2085359] [Reference Citation Analysis]
16 Cho SM, Esmail A, Raza A, Dacha S, Abdelrahim M. Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma. Cancers (Basel) 2022;14:2641. [PMID: 35681621 DOI: 10.3390/cancers14112641] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Bär SI, Dittmer A, Nitzsche B, Ter-Avetisyan G, Fähling M, Klefenz A, Kaps L, Biersack B, Schobert R, Höpfner M. Chimeric HDAC and the cytoskeleton inhibitor broxbam as a novel therapeutic strategy for liver cancer. Int J Oncol 2022;60:73. [PMID: 35485292 DOI: 10.3892/ijo.2022.5363] [Reference Citation Analysis]
18 Parsons M, Lloyd S, Johnson S, Scaife C, Soares H, Kim R, Kim R, Garrido-Laguna I, Tao R. The Implications of Treatment Delays in Adjuvant Therapy for Resected Cholangiocarcinoma Patients. J Gastrointest Cancer 2022. [PMID: 35445343 DOI: 10.1007/s12029-022-00820-4] [Reference Citation Analysis]
19 Xiong W, Zhang A, Xiao X, Liu W. CircSETD3 (hsa_circ_0000567) inhibits proliferation and induces apoptosis in cholangiocarcinoma cells via downregulation of microRNA-421 expression. Bioengineered 2022;13:10191-201. [PMID: 35435120 DOI: 10.1080/21655979.2022.2061283] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Kahaleh M, Raijman I, Gaidhane M, Tyberg A, Sethi A, Slivka A, Adler DG, Sejpal D, Shahid H, Sarkar A, Martins F, Boumitri C, Burton S, Bertani H, Tarnasky P, Gress F, Gan I, Ardengh JC, Kedia P, Arnelo U, Jamidar P, Shah RJ, Robles-Medranda C. Digital Cholangioscopic Interpretation: When North Meets the South. Dig Dis Sci 2022;67:1345-51. [PMID: 33783691 DOI: 10.1007/s10620-021-06961-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Peixoto RD, Ferreira AR, Cleary JM, Fogacci JP, Vasconcelos JP, Jácome AA. Risk of Cancer in Inflammatory Bowel Disease and Pitfalls in Oncologic Therapy. J Gastrointest Cancer 2022. [PMID: 35288863 DOI: 10.1007/s12029-022-00816-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Chang H, Yao Y. lncRNA TMPO antisense RNA 1 promotes the malignancy of cholangiocarcinoma cells by regulating let-7g-5p/ high-mobility group A1 axis. Bioengineered 2022;13:2889-901. [PMID: 35040749 DOI: 10.1080/21655979.2022.2025700] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Gonzalez-Carmona MA, Möhring C, Mahn R, Zhou T, Bartels A, Sadeghlar F, Bolch M, Vogt A, Kaczmarek DJ, Heling DJ, Dold L, Nattermann J, Branchi V, Matthaei H, Manekeller S, Kalff JC, Strassburg CP, Mohr RU, Weismüller TJ. Impact of regular additional endobiliary radiofrequency ablation on survival of patients with advanced extrahepatic cholangiocarcinoma under systemic chemotherapy. Sci Rep 2022;12:1011. [PMID: 35046437 DOI: 10.1038/s41598-021-04297-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
24 Boyd LNC, Ali M, Kam L, Puik JR, Rodrigues SMF, Zwart ES, Daams F, Zonderhuis BM, Meijer LL, Le Large TYS, Giovannetti E, van Laarhoven HWM, Kazemier G. The Diagnostic Value of the CA19-9 and Bilirubin Ratio in Patients with Pancreatic Cancer, Distal Bile Duct Cancer and Benign Periampullary Diseases, a Novel Approach. Cancers (Basel) 2022;14:344. [PMID: 35053506 DOI: 10.3390/cancers14020344] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
25 Deng J, Liu L, Li L, Sun J, Yan F. Hesperidin delays cell cycle progression into the G0/G1 phase via suspension of MAPK signaling pathway in intrahepatic cholangiocarcinoma. J Biochem Mol Toxicol 2022;:e22981. [PMID: 34984768 DOI: 10.1002/jbt.22981] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Lv T, Hu H, Liu F, Regmi P, Jin Y, Li F. The effect of trans arterial chemoembolization in the management of intrahepatic cholangiocarcinoma. A systematic review and meta-analysis. European Journal of Surgical Oncology 2022. [DOI: 10.1016/j.ejso.2022.01.009] [Reference Citation Analysis]
27 Yan X, Zhuang LP, Ning ZY, Wang P, Meng ZQ. Addition of thermal ablation to systemic chemotherapy for the treatment of unresectable intrahepatic cholangiocarcinoma: a propensity score matching analysis. Expert Rev Gastroenterol Hepatol 2021;:1-8. [PMID: 34937481 DOI: 10.1080/17474124.2022.2021067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
28 Spolverato G, Glavas D, Hewitt DB, Brown ZJ, Capelli G, Bergamo F, Rizzato MD, Pawlik TM. Advances in pharmacotherapy for cholangiocarcinoma: from conventional therapies to targeted drugs. Expert Opin Pharmacother 2021;:1-9. [PMID: 34964678 DOI: 10.1080/14656566.2021.2020250] [Reference Citation Analysis]
29 Wang D, Xiong F, Wu G, Liu W, Wang B, Chen Y. MiR-155-5p suppresses SOX1 to promote proliferation of cholangiocarcinoma via RAF/MEK/ERK pathway. Cancer Cell Int 2021;21:656. [PMID: 34876142 DOI: 10.1186/s12935-021-02374-0] [Reference Citation Analysis]
30 Ran X, Luo J, Zuo C, Huang Y, Sui Y, Cen J, Tang S. Developing metabolic gene signatures to predict intrahepatic cholangiocarcinoma prognosis and mining a miRNA regulatory network. J Clin Lab Anal 2021;:e24107. [PMID: 34871464 DOI: 10.1002/jcla.24107] [Reference Citation Analysis]
31 Möhring C, Feder J, Mohr RU, Sadeghlar F, Bartels A, Mahn R, Zhou T, Marinova M, Feldmann G, Brossart P, von Websky M, Matthaei H, Manekeller S, Glowka T, Kalff JC, Weismüller TJ, Strassburg CP, Gonzalez-Carmona MA. First Line and Second Line Chemotherapy in Advanced Cholangiocarcinoma and Impact of Dose Reduction of Chemotherapy: A Retrospective Analysis. Front Oncol 2021;11:717397. [PMID: 34858809 DOI: 10.3389/fonc.2021.717397] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Nie H, Wang F, Xiong Q, Dong L, Fang J, Wang H, Zhao Q. Novel biliopancreatic duct endoscope combining optical coherence tomography with intraductal US for exploring the bile duct: a diagnostic study in a porcine model. Gastrointest Endosc 2021;94:1136-42. [PMID: 34274345 DOI: 10.1016/j.gie.2021.07.009] [Reference Citation Analysis]
33 Shen X, Zhao H, Jin X, Chen J, Yu Z, Ramen K, Zheng X, Wu X, Shan Y, Bai J, Zhang Q, Zeng Q. Development and validation of a machine learning-based nomogram for prediction of intrahepatic cholangiocarcinoma in patients with intrahepatic lithiasis. Hepatobiliary Surg Nutr 2021;10:749-65. [PMID: 35004943 DOI: 10.21037/hbsn-20-332] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
34 Poosekeaw P, Pairojkul C, Sripa B, Sa Ngiamwibool P, Iamsaard S, Sakonsinsiri C, Thanan R, Ungarreevittaya P. Adaptor protein XB130 regulates the aggressiveness of cholangiocarcinoma. PLoS One 2021;16:e0259075. [PMID: 34780466 DOI: 10.1371/journal.pone.0259075] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Saffioti F, Mavroeidis VK. Review of incidence and outcomes of treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis. World J Gastrointest Oncol 2021; 13(10): 1336-1366 [PMID: 34721770 DOI: 10.4251/wjgo.v13.i10.1336] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
36 Zeng FL, Chen JF. Application of Immune Checkpoint Inhibitors in the Treatment of Cholangiocarcinoma. Technol Cancer Res Treat 2021;20:15330338211039952. [PMID: 34528830 DOI: 10.1177/15330338211039952] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
37 Duan X, Yang J, Jiang B, Duan W, Wei R, Zhang H, Mao X. Knockdown of PSMC2 contributes to suppression of cholangiocarcinoma development by regulating CDK1. Aging (Albany NY) 2021;13:21325-44. [PMID: 34499615 DOI: 10.18632/aging.203463] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
38 Zheng YW, Miao XY, Xiong L, Chen B, Kong FH, Zhou JJ, Liu ZT, Wen Y, Zhang ZJ, Zou H. Sulfasalazine Sensitizes Polyhematoporphyrin-Mediated Photodynamic Therapy in Cholangiocarcinoma by Targeting xCT. Front Pharmacol 2021;12:723488. [PMID: 34483935 DOI: 10.3389/fphar.2021.723488] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
39 Lei GL, Li Z, Li YY, Hong ZX, Wang S, Bai ZF, Sun F, Yan J, Yu LX, Yang PH, Yang ZY. Long noncoding RNA FAM66C promotes tumor progression and glycolysis in intrahepatic cholangiocarcinoma by regulating hsa-miR-23b-3p/KCND2 axis. Environ Toxicol 2021;36:2322-32. [PMID: 34418280 DOI: 10.1002/tox.23346] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
40 Sharif AF, Gameel DEGE, Abdo SAE, Elgebally EI, Fayed MM. Evaluation of Pediatric Early Warning System and Drooling Reluctance Oropharynx Others Leukocytosis scores as prognostic tools for pediatric caustic ingestion: a two-center, cross-sectional study. Environ Sci Pollut Res Int 2021. [PMID: 34420162 DOI: 10.1007/s11356-021-15988-8] [Reference Citation Analysis]
41 Prompipak J, Senawong T, Sripa B, Ketterman AJ, Utaiwat S, Woranam K, Jeeunngoi J, Senawong G. Anticancer effects of the combined Thai noni juice ethanolic extracts and 5-fluorouracil against cholangiocarcinoma cells in vitro and in vivo. Sci Rep 2021;11:14866. [PMID: 34290264 DOI: 10.1038/s41598-021-94049-z] [Reference Citation Analysis]
42 Tanaka E, Uchida D, Shiraha H, Kato H, Ohyama A, Iwamuro M, Watanabe M, Kumon H, Okada H. Promising Gene Therapy Using an Adenovirus Vector Carrying REIC/Dkk-3 Gene for the Treatment of Biliary Cancer. Curr Gene Ther 2020;20:64-70. [PMID: 32148193 DOI: 10.2174/1566523220666200309125709] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
43 Chen W, Song J, Liu S, Tang B, Shen L, Zhu J, Fang S, Wu F, Zheng L, Qiu R, Chen C, Gao Y, Tu J, Zhao Z, Ji J. USP9X promotes apoptosis in cholangiocarcinoma by modulation expression of KIF1Bβ via deubiquitinating EGLN3. J Biomed Sci 2021;28:44. [PMID: 34112167 DOI: 10.1186/s12929-021-00738-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
44 Hozaka Y, Seki N, Tanaka T, Asai S, Moriya S, Idichi T, Wada M, Tanoue K, Kawasaki Y, Mataki Y, Kurahara H, Ohtsuka T. Molecular Pathogenesis and Regulation of the miR-29-3p-Family: Involvement of ITGA6 and ITGB1 in Intra-Hepatic Cholangiocarcinoma. Cancers (Basel) 2021;13:2804. [PMID: 34199886 DOI: 10.3390/cancers13112804] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
45 Rexha I, Laage-Gaupp F, Chapiro J, Miszczuk MA, van Breugel JMM, Lin M, Konstantinidis M, Duran R, Gebauer B, Georgiades C, Hong K, Nezami N. Role of 3D quantitative tumor analysis for predicting overall survival after conventional chemoembolization of intrahepatic cholangiocarcinoma. Sci Rep 2021;11:9337. [PMID: 33927226 DOI: 10.1038/s41598-021-88426-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
46 Sun HB, Zhang GC, Liu J, Nie CS. Long noncoding RNA LINC00184 facilitates the proliferation, metastasis, and adenine metabolism of cholangiocarcinoma via modulating hsa-miR-23b-3p/ANXA2 axis. Environ Toxicol 2021;36:1576-90. [PMID: 33913242 DOI: 10.1002/tox.23154] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
47 Thongchot S, Vidoni C, Ferraresi A, Loilome W, Khuntikeo N, Sangkhamanon S, Titapun A, Isidoro C, Namwat N. Cancer-Associated Fibroblast-Derived IL-6 Determines Unfavorable Prognosis in Cholangiocarcinoma by Affecting Autophagy-Associated Chemoresponse. Cancers (Basel) 2021;13:2134. [PMID: 33925189 DOI: 10.3390/cancers13092134] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
48 Wang Q, An Y, Wang F, Zhang G, Zhang L, Dong H, Xin J, Li Y, Ji S, Guo X. OSchol: an online consensus survival web server for cholangiocarcinoma prognosis analysis. HPB (Oxford) 2021;23:545-50. [PMID: 32888851 DOI: 10.1016/j.hpb.2020.08.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
49 Trudeau NA, Lawton JM, Patel ND. Pemigatinib-induced nail changes - A case report. J Oncol Pharm Pract 2021;27:1795-8. [PMID: 33736556 DOI: 10.1177/10781552211002629] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
50 Duan X, Yang J, Jiang B, Duan W, Wei R, Zhang H, Mao X. Identification of chondroitin polymerizing factor (CHPF) as tumor promotor in cholangiocarcinoma through regulating cell proliferation, cell apoptosis and cell migration. Cell Cycle 2021;20:591-602. [PMID: 33651657 DOI: 10.1080/15384101.2021.1890951] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
51 Han P, Shang J, Chen D, Li S, Fan R, Li R, Li H, Zhang S, Shen D. Baicalein mediates anticancer effect on cholangiocarcinoma through co-targeting the AKT/NF-κB and STAT3 signaling pathway. Process Biochemistry 2021;102:304-14. [DOI: 10.1016/j.procbio.2021.01.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
52 Naseer M, Hadi S, Syed A, Safdari A, Tahan V. Exosomes: A new frontier under the spotlight for diagnosis and treatment of gastrointestinal diseases. World J Meta-Anal 2021; 9(1): 12-28 [DOI: 10.13105/wjma.v9.i1.12] [Reference Citation Analysis]
53 Zhu B, Qian W, Han C, Bai T, Hou X. Piezo 1 activation facilitates cholangiocarcinoma metastasis via Hippo/YAP signaling axis. Mol Ther Nucleic Acids 2021;24:241-52. [PMID: 33767919 DOI: 10.1016/j.omtn.2021.02.026] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
54 Amin NEL, Hansen TF, Fernebro E, Ploen J, Eberhard J, Lindebjerg J, Jensen LH. Randomized Phase II trial of combination chemotherapy with panitumumab or bevacizumab for patients with inoperable biliary tract cancer without KRAS exon 2 mutations. Int J Cancer 2021;149:119-26. [PMID: 33561312 DOI: 10.1002/ijc.33509] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
55 Na-Bangchang K, Kulma I, Plengsuriyakarn T, Tharavanij T, Kotawng K, Chemung A, Muhamad N, Karbwang J. Phase I clinical trial to evaluate the safety and pharmacokinetics of capsule formulation of the standardized extract of Atractylodes lancea. J Tradit Complement Med 2021;11:343-55. [PMID: 34195029 DOI: 10.1016/j.jtcme.2021.02.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
56 Jiao CY, Feng QC, Li CX, Wang D, Han S, Zhang YD, Jiang WJ, Chang J, Wang X, Li XC. BUB1B promotes extrahepatic cholangiocarcinoma progression via JNK/c-Jun pathways. Cell Death Dis 2021;12:63. [PMID: 33431813 DOI: 10.1038/s41419-020-03234-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
57 Kovač J. Intrahepatic Cholangiocarcinoma and Mixed Tumors. Imaging of the Liver and Intra-hepatic Biliary Tract 2021. [DOI: 10.1007/978-3-030-39021-1_6] [Reference Citation Analysis]
58 Sawas T, Marya N, Levy M. The Role of Endoscopic Ultrasound in Cholangiocarcinoma. Diagnosis and Management of Cholangiocarcinoma 2021. [DOI: 10.1007/978-3-030-70936-5_13] [Reference Citation Analysis]
59 Kaewmeesri P, Kukongviriyapan V, Prawan A, Kongpetch S, Senggunprai L. Cucurbitacin B Diminishes Metastatic Behavior of Cholangiocarcinoma Cells by Suppressing Focal Adhesion Kinase. Asian Pac J Cancer Prev 2021;22:219-25. [PMID: 33507702 DOI: 10.31557/APJCP.2021.22.1.219] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
60 Liu Z, Pan L, Yan X, Duan X. The long noncoding RNA DLGAP1-AS2 facilitates cholangiocarcinoma progression via miR-505 and GALNT10. FEBS Open Bio 2021;11:413-22. [PMID: 33301605 DOI: 10.1002/2211-5463.13061] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
61 Chahal D, Shamatutu C, Salh B, Davies J. The impact of primary sclerosing cholangitis or inflammatory bowel disease on cholangiocarcinoma phenotype, therapy, and survival. JGH Open 2020;4:1128-34. [PMID: 33319047 DOI: 10.1002/jgh3.12405] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
62 Zheng Y, Wu F, Rong W, Liu Y, Siqin T, Wang L, Wu J. Prognostic value of the controlling nutritional status (CONUT) score in intrahepatic cholangiocarcinoma patients especially who had long-time alcohol consumption. J Clin Biochem Nutr 2020;67:323-31. [PMID: 33293775 DOI: 10.3164/jcbn.20-27] [Reference Citation Analysis]
63 Zhang J, Hang C, Jiang T, Yi S, Shao W, Li W, Lin D. Nuclear Magnetic Resonance-Based Metabolomic Analysis of the Anticancer Effect of Metformin Treatment on Cholangiocarcinoma Cells. Front Oncol 2020;10:570516. [PMID: 33330044 DOI: 10.3389/fonc.2020.570516] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
64 Darbà J, Marsà A. Analysis of hospital incidence and direct medical costs of intrahepatic cholangiocarcinoma in Spain (2000-2018). Expert Rev Pharmacoecon Outcomes Res 2021;21:425-31. [PMID: 33161795 DOI: 10.1080/14737167.2021.1842201] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
65 Ma J, Zhang H, Tang K, Huang B. Tumor-derived microparticles in tumor immunology and immunotherapy. Eur J Immunol 2020;50:1653-62. [PMID: 32976623 DOI: 10.1002/eji.202048548] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
66 Zhou P, Song T, Sun C, He N, Cheng Q, Xiao X, Ran J, Liu M, Xie S. USP21 upregulation in cholangiocarcinoma promotes cell proliferation and migration in a deubiquitinase-dependent manner. Asia Pac J Clin Oncol 2020. [PMID: 33052017 DOI: 10.1111/ajco.13480] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
67 Yao X, Huang X, Yang C, Hu A, Zhou G, Lei J, Shu J. A Novel Approach to Assessing Differentiation Degree and Lymph Node Metastasis of Extrahepatic Cholangiocarcinoma: Prediction Using a Radiomics-Based Particle Swarm Optimization and Support Vector Machine Model. JMIR Med Inform 2020;8:e23578. [PMID: 33016889 DOI: 10.2196/23578] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
68 Yangngam S, Thongchot S, Pongpaibul A, Vaeteewoottacharn K, Pinlaor S, Thuwajit P, Okada S, Hermoso MA, Thuwajit C. High level of interleukin-33 in cancer cells and cancer-associated fibroblasts correlates with good prognosis and suppressed migration in cholangiocarcinoma. J Cancer 2020;11:6571-81. [PMID: 33046978 DOI: 10.7150/jca.48327] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
69 Bai M, Fu W, Su G, Cao J, Gao L, Huang C, Ma H, Zhang J, Yue P, Bai B, Lin Y, Meng W, Li X. The role of extracellular vesicles in cholangiocarcinoma. Cancer Cell Int 2020;20. [DOI: 10.1186/s12935-020-01526-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
70 Yao X, Huang X, Yang C, Hu A, Zhou G, Lei J, Shu J. A Novel Approach to Assessing Differentiation Degree and Lymph Node Metastasis of Extrahepatic Cholangiocarcinoma: Prediction Using a Radiomics-Based Particle Swarm Optimization and Support Vector Machine Model (Preprint).. [DOI: 10.2196/preprints.23578] [Reference Citation Analysis]
71 Parama D, Boruah M, Yachna K, Rana V, Banik K, Harsha C, Thakur KK, Dutta U, Arya A, Mao X, Ahn KS, Kunnumakkara AB. Diosgenin, a steroidal saponin, and its analogs: Effective therapies against different chronic diseases. Life Sci 2020;260:118182. [PMID: 32781063 DOI: 10.1016/j.lfs.2020.118182] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 17.7] [Reference Citation Analysis]
72 Ji D, Zheng W, Huang P, Yao Y, Zhong X, Kang P, Wang Z, Shi G, Xu Y, Cui Y. Huaier Restrains Cholangiocarcinoma Progression in vitro and in vivo Through Modulating lncRNA TP73-AS1 and Inducing Oxidative Stress. Onco Targets Ther 2020;13:7819-37. [PMID: 32848417 DOI: 10.2147/OTT.S257738] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
73 Yacoub H, Hassine H, Boukriba S, Haouet S, Ayari A, Kchir H, Maamouri N. Intrahepatic cholangiocarcinoma mimicking a liver abscess. Clin Case Rep 2020;8:2510-3. [PMID: 33363768 DOI: 10.1002/ccr3.3201] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
74 Wang K, Zhang Y, Yang X, Chen T, Han T. Analysis of differentially expressed mRNAs and the prognosis of cholangiocarcinoma based on TCGA database. Transl Cancer Res 2020;9:4739-49. [PMID: 35117837 DOI: 10.21037/tcr-20-812] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
75 Mohr R, Özdirik B, Knorr J, Wree A, Demir M, Tacke F, Roderburg C. In Vivo Models for Cholangiocarcinoma-What Can We Learn for Human Disease? Int J Mol Sci 2020;21:E4993. [PMID: 32679791 DOI: 10.3390/ijms21144993] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
76 Shi XQ, Zhang JY, Tian H, Tang LN, Li AL. Role of adjuvant (chemo)radiotherapy for resected extrahepatic cholangiocarcinoma: a meta-analysis. J Zhejiang Univ Sci B 2020;21:549-59. [PMID: 32633109 DOI: 10.1631/jzus.B1900691] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
77 Dondossola D, Ghidini M, Grossi F, Rossi G, Foschi D. Practical review for diagnosis and clinical management of perihilar cholangiocarcinoma. World J Gastroenterol 2020; 26(25): 3542-3561 [PMID: 32742125 DOI: 10.3748/wjg.v26.i25.3542] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 22] [Article Influence: 7.7] [Reference Citation Analysis]
78 Gao Y, Zhang H, Zhou N, Xu P, Wang J, Gao Y, Jin X, Liang X, Lv J, Zhang Y, Tang K, Ma J, Zhang H, Xie J, Yao F, Tong W, Liu Y, Wang X, Huang B. Methotrexate-loaded tumour-cell-derived microvesicles can relieve biliary obstruction in patients with extrahepatic cholangiocarcinoma. Nat Biomed Eng 2020;4:743-53. [PMID: 32632227 DOI: 10.1038/s41551-020-0583-0] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 14.0] [Reference Citation Analysis]
79 Peng YT, Zhou CY, Lin P, Wen DY, Wang XD, Zhong XZ, Pan DH, Que Q, Li X, Chen L, He Y, Yang H. Preoperative Ultrasound Radiomics Signatures for Noninvasive Evaluation of Biological Characteristics of Intrahepatic Cholangiocarcinoma. Acad Radiol 2020;27:785-97. [PMID: 31494003 DOI: 10.1016/j.acra.2019.07.029] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
80 Zheng Y, Wu F, Rong W, Liu Y, Siqin T, Wang L, Wu J. Prognostic value of the controlling nutritional status (CONUT) score in intrahepatic cholangiocarcinoma patients especially who had long-time alcohol consumption. J Clin Biochem Nutr 2020;67:323-31. [PMID: 33293775 DOI: 10.3164/jcbn.20-27] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
81 Belfiore MP, Reginelli A, Maggialetti N, Carbone M, Giovine S, Laporta A, Urraro F, Nardone V, Grassi R, Cappabianca S, Brunese L. Preliminary results in unresectable cholangiocarcinoma treated by CT percutaneous irreversible electroporation: feasibility, safety and efficacy. Med Oncol 2020;37:45. [PMID: 32270353 DOI: 10.1007/s12032-020-01360-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
82 Zou H, Wang F, Zhou JJ, Liu X, He Q, Wang C, Zheng YW, Wen Y, Xiong L. Application of photodynamic therapy for liver malignancies. J Gastrointest Oncol 2020;11:431-42. [PMID: 32399283 DOI: 10.21037/jgo.2020.02.10] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
83 Chang W, Wang Y, Li W, Geng Z. Long non-coding RNA myocardial infarction associated transcript promotes the proliferation of cholangiocarcinoma cells by targeting miR-551b-3p/CCND1 axis. Clin Exp Pharmacol Physiol 2020;47:1067-75. [PMID: 32064660 DOI: 10.1111/1440-1681.13283] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
84 Grubman O, Taylor D, Rayapudi M, Brustman L. A case report of a pregnant woman diagnosed with intrahepatic cholangiocarcinoma (ICC) complicated by opioid tolerance. Case Reports in Perinatal Medicine 2020;9:20190062. [DOI: 10.1515/crpm-2019-0062] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
85 Ren B, Guo Q, Yang Y, Liu L, Wei S, Chen W, Tian Y. A meta-analysis of the efficacy of postoperative adjuvant radiotherapy versus no radiotherapy for extrahepatic cholangiocarcinoma and gallbladder carcinoma. Radiat Oncol 2020;15:15. [PMID: 31941520 DOI: 10.1186/s13014-020-1459-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
86 Zhang XM, Liu ZL, Qiu B, Xu YF, Pan C, Zhang ZL. Downregulation of EVI1 Expression Inhibits Cell Proliferation and Induces Apoptosis in Hilar Cholangiocarcinoma via the PTEN/AKT Signalling Pathway. J Cancer 2020;11:1412-23. [PMID: 32047548 DOI: 10.7150/jca.31903] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
87 Wu Z, Liu R, Xiong L, Miao X, Li D, Zou Q, Yuan Y, Yang Z. Prognostic and Clinicopathological Significance of EphB3 and Dysadherin Expression in Extrahepatic Cholangiocarcinoma. Cancer Manag Res 2020;12:221-32. [PMID: 32021438 DOI: 10.2147/CMAR.S232278] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
88 Kelly PJ. Perihilar and Distal Extrahepatic Bile Duct Carcinoma. Histopathology Reporting 2020. [DOI: 10.1007/978-3-030-27828-1_10] [Reference Citation Analysis]
89 Angeles C, Lascano D, Veillette G. Hepatopancreaticobiliary Surgery in the Elderly. Surgical Decision Making in Geriatrics 2020. [DOI: 10.1007/978-3-030-47963-3_24] [Reference Citation Analysis]
90 Hong ZF, Zhang WQ, Wang SJ, Li SY, Shang J, Liu F, Shen DY. Upregulation of DPY30 promotes cell proliferation and predicts a poor prognosis in cholangiocarcinoma. Biomed Pharmacother 2020;123:109766. [PMID: 31846841 DOI: 10.1016/j.biopha.2019.109766] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
91 Lee EJ, Chung HW, Jo JH, So Y. Radioembolization for the Treatment of Primary and Metastatic Liver Cancers. Nucl Med Mol Imaging 2019;53:367-73. [PMID: 31867071 DOI: 10.1007/s13139-019-00615-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
92 Liu J, Liu W, Li H, Deng Q, Yang M, Li X, Liang Z. Identification of key genes and pathways associated with cholangiocarcinoma development based on weighted gene correlation network analysis. PeerJ 2019;7:e7968. [PMID: 31687280 DOI: 10.7717/peerj.7968] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
93 Fehling SC, Miller AL, Garcia PL, Vance RB, Yoon KJ. The combination of BET and PARP inhibitors is synergistic in models of cholangiocarcinoma. Cancer Lett 2020;468:48-58. [PMID: 31605774 DOI: 10.1016/j.canlet.2019.10.011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
94 Sangsin A, Saiudom D, Pongmanee S, Saengsin J, Leerapun T, Murakami H. Natural History and Prognostic Factors of Cholangiocarcinoma With Spinal Metastasis: A 10-Year Single Center Study. Clin Spine Surg 2018;31:E160-5. [PMID: 29596214 DOI: 10.1097/BSD.0000000000000625] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
95 Wang S, Hu Y, Lv X, Li B, Gu D, Li Y, Sun Y, Su Y. Circ-0000284 arouses malignant phenotype of cholangiocarcinoma cells and regulates the biological functions of peripheral cells through cellular communication. Clin Sci (Lond). 2019;133:1935-1953. [PMID: 31501232 DOI: 10.1042/cs20190589] [Cited by in Crossref: 46] [Cited by in F6Publishing: 52] [Article Influence: 11.5] [Reference Citation Analysis]
96 Huang L, Jiang X, Kang P, Wang Z, Leng K, Ji D, Xu Y, Wang H, Cui Y. Long non-coding RNA NNT-AS1 functions as an oncogenic gene through modulating miR-485/BCL9 in cholangiocarcinoma. Cancer Manag Res 2019;11:7739-49. [PMID: 31616187 DOI: 10.2147/CMAR.S207801] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
97 Fu Z, Ma K, Dong B, Zhao C, Che C, Dong C, Zhang R, Wang H, Wang X, Liang R. The synergistic antitumor effect of Huaier combined with 5-Florouracil in human cholangiocarcinoma cells. BMC Complement Altern Med 2019;19:203. [PMID: 31391034 DOI: 10.1186/s12906-019-2614-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
98 Guo SS, Wang Y, Fan QX. Raddeanin A promotes apoptosis and ameliorates 5-fluorouracil resistance in cholangiocarcinoma cells. World J Gastroenterol 2019; 25(26): 3380-3391 [PMID: 31341363 DOI: 10.3748/wjg.v25.i26.3380] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
99 Lee RM, Liu Y, Gamboa AC, Zaidi MY, Kooby DA, Shah MM, Cardona K, Russell MC, Maithel SK. Race, ethnicity, and socioeconomic factors in cholangiocarcinoma: What is driving disparities in receipt of treatment? J Surg Oncol. 2019;120:611-623. [PMID: 31301148 DOI: 10.1002/jso.25632] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
100 Chang W, Wang Y, Li W, Shi L, Geng Z. MicroRNA-551b-3p inhibits tumour growth of human cholangiocarcinoma by targeting Cyclin D1. J Cell Mol Med. 2019;23:4945-4954. [PMID: 31199052 DOI: 10.1111/jcmm.14312] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
101 Song BG, Park JK, Kim HS, Kim K, Park JK, Lee KH, Lee KT, Lee JK. Prognosis and prognostic factors in patients with advanced biliary tract cancer depending on its anatomical location. Scand J Gastroenterol 2019;54:740-5. [PMID: 31136212 DOI: 10.1080/00365521.2019.1619827] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
102 Vaeteewoottacharn K, Pairojkul C, Kariya R, Muisuk K, Imtawil K, Chamgramol Y, Bhudhisawasdi V, Khuntikeo N, Pugkhem A, Saeseow OT, Silsirivanit A, Wongkham C, Wongkham S, Okada S. Establishment of Highly Transplantable Cholangiocarcinoma Cell Lines from a Patient-Derived Xenograft Mouse Model. Cells 2019;8:E496. [PMID: 31126020 DOI: 10.3390/cells8050496] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
103 Chiang KC, Huang ST, Wu RC, Huang SC, Yeh TS, Chen MH, Hsu JT, Chen LW, Kuo SF, Chueh HY, Juang HH, Hung SI, Yeh CN, Pang JS. Interferon α-inducible protein 27 is an oncogene and highly expressed in cholangiocarcinoma patients with poor survival. Cancer Manag Res 2019;11:1893-905. [PMID: 30881116 DOI: 10.2147/CMAR.S196485] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
104 Gonzalez-Carmona MA, Bolch M, Jansen C, Vogt A, Sampels M, Mohr RU, van Beekum K, Mahn R, Praktiknjo M, Nattermann J, Trebicka J, Branchi V, Matthaei H, Manekeller S, Kalff JC, Strassburg CP, Weismüller TJ. Combined photodynamic therapy with systemic chemotherapy for unresectable cholangiocarcinoma. Aliment Pharmacol Ther 2019;49:437-47. [PMID: 30637783 DOI: 10.1111/apt.15050] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 10.5] [Reference Citation Analysis]
105 Liu S, Zhou L, An L. Implementation of comprehensive rehabilitation therapy in postoperative care of patients with cholangiocarcinoma and its impact on patients' quality of life. Exp Ther Med 2019;17:2703-7. [PMID: 30906460 DOI: 10.3892/etm.2019.7215] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
106 Nagata K, Einama T, Kimura A, Murayama M, Takeo H, Nishikawa M, Hoshikawa M, Noro T, Ogata S, Aosasa S, Kajiwara Y, Shinto E, Yaguchi Y, Hiraki S, Tsujimoto H, Hase K, Ueno H, Yamamoto J. A case of intrahepatic cholangiocarcinoma that was difficult to diagnose prior to surgery: A case report. Oncol Lett 2019;17:823-30. [PMID: 30655835 DOI: 10.3892/ol.2018.9666] [Reference Citation Analysis]
107 Francis AP, Chang M, Dolin CD, Chervenak J, Cardonick E. Recurrent Cholangiocarcinoma in Pregnancy: A Case Report. AJP Rep 2018;8:e261-3. [PMID: 30425881 DOI: 10.1055/s-0038-1675376] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
108 Prueksapanich P, Piyachaturawat P, Aumpansub P, Ridtitid W, Chaiteerakij R, Rerknimitr R. Liver Fluke-Associated Biliary Tract Cancer. Gut Liver 2018;12:236-45. [PMID: 28783896 DOI: 10.5009/gnl17102] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 9.0] [Reference Citation Analysis]
109 Zheng X, Chen B, Wu JX, Jia AY, Rong WQ, Wang LM, Wu F, Zhao YT, Li YX, Wang WH. Benefit of adjuvant radiotherapy following narrow-margin hepatectomy in patients with intrahepatic cholangiocarcinoma that adhere to major vessels. Cancer Manag Res 2018;10:3973-81. [PMID: 30310318 DOI: 10.2147/CMAR.S172940] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
110 Marquardt S, Kirstein MM, Brüning R, Zeile M, Ferrucci PF, Prevoo W, Radeleff B, Trillaud H, Tselikas L, Vicente E, Wiggermann P, Manns MP, Vogel A, Wacker FK. Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival. Eur Radiol 2019;29:1882-92. [PMID: 30255257 DOI: 10.1007/s00330-018-5729-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 4.2] [Reference Citation Analysis]
111 Siripongsakun S, Vidhyarkorn S, Charuswattanakul S, Mekraksakit P, Sungkasubun P, Yodkhunnathum N, Tangruangkiat S, Ritlumlert N, Sricharunrat T, Jaroenpatarapesaj S, Soonklang K, Kulthanmanusorn A, Auewarakul CU, Mahidol C. Ultrasound surveillance for cholangiocarcinoma in an endemic area: A prove of survival benefits. J Gastroenterol Hepatol 2018;33:1383-8. [PMID: 29247982 DOI: 10.1111/jgh.14074] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
112 Daya M, Loilome W, Techasen A, Thanee M, Sa-Ngiamwibool P, Titapun A, Yongvanit P, Namwat N. Progranulin modulates cholangiocarcinoma cell proliferation, apoptosis, and motility via the PI3K/pAkt pathway. Onco Targets Ther 2018;11:395-408. [PMID: 29403285 DOI: 10.2147/OTT.S155511] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
113 Garcia-aroz S, Xu M, Chapman WC. Liver Transplantation for Other Cancers. Primary and Metastatic Liver Tumors 2018. [DOI: 10.1007/978-3-319-91977-5_24] [Reference Citation Analysis]
114 Murali N, Savic LJ, Nezami N, Chapiro J, Geschwind J. Regional Liver-Directed Therapies for Intrahepatic Cholangiocarcinoma. Primary and Metastatic Liver Tumors 2018. [DOI: 10.1007/978-3-319-91977-5_9] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
115 Ma FC, Yu Q, Zeng ZM, He RQ, Mo CH, Zhong JC, Ma J, Feng ZB, Chen G, Hu XH. Progression-free survival of up to 8 months of an advanced intrahepatic cholangiocarcinoma patient treated with apatinib: a case report. Onco Targets Ther 2017;10:5237-42. [PMID: 29138576 DOI: 10.2147/OTT.S146051] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
116 Huang Y, You L, Xie W, Ning L, Lang J. Smoking and risk of cholangiocarcinoma: a systematic review and meta-analysis. Oncotarget 2017;8:100570-81. [PMID: 29246002 DOI: 10.18632/oncotarget.20141] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
117 Chinchilla-López P, Aguilar-Olivos NE, García-Gómez J, Hernández-Alejandro KK, Chablé-Montero F, Motola-Kuba D, Patel T, Méndez-Sánchez N. Prevalence, Risk Factors, and Survival of Patients with Intrahepatic Cholangiocarcinoma. Ann Hepatol 2017;16:565-8. [PMID: 28611259 DOI: 10.5604/01.3001.0010.0293] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]